Business
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through
About this update from Reviva Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 -- Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected Q3 2026 - CUPERTINO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the first quarter ended March 31, 2026 and summarized recent business highlights. “During the first quarter, we further refined our development strategy to strengthen the long-term value of brilaroxazine,” said Laxminarayan Bhat, Founder, President, and CEO of Reviva. “A key priority is to incorporate a new form of brilaroxazine into our clinical and regulatory pathway, which we believe has the potential to extend patent protection and commercial exclusivity of the program. We expect U.S. Food and Drug Administration (FDA) feedback on this strategy in mid-2026. In parallel, we are preparing to initiate RECOVER-2, our registrational Phase 3 trial in schizophrenia, with patient enrollment expected to begin in the third quarter of 2026. With multiple milestones ahead in 2026, we are committed to disciplined execution as we advance brilaroxazine as a differentiated treatment option for patients with schizophrenia and other neuropsychiatric disorders.” Clinical Program and Business Highlights U.S. composition of matter provisional patent application filed seeking an accelerated review process for a new form of brilaroxazine designed to extend patent life and commercial exclusivity potentially through 2046.Planned use of a new form of brilaroxazine in the RECOVER-2 Phase 3 trial in schizophrenia and in the future New Drug Application (NDA) submission. The Company is optimistic about receiving FDA alignment on this strategy, with FDA feedback on using the new brilaroxazine form in the RECOVER-2 Phase 3 trial expected in mid-2026.Published clinical vocal biomarker data from the RECOVER Phase 3 clinical trial highlightin...